for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
completion around



Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Official Title

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies


Cancer, Rollover, pan-tumor, Leucovorin, Bevacizumab, Pembrolizumab, Nivolumab, Ipilimumab, Relatlimab, Sunitinib, Capecitabine, Oxaliplatin, Fluorouracil, Pemetrexed, Temozolomide, Daratumumab, Trametinib, Rucaparib, Cabozantinib, Nivolumab + Relatlimab, Regorafinib, Enzalutamide, B1: Nivolumab + Ipilimumab, B2: Nivolumab + Ipilimumab + Cabozantinib, B3: Nivolumab + Ipilimumab + Trametinib, C5: Relatlimab + Nivolumab + Ipilimumab, C6: Relatlimab + Nivolumab + Capecitabine, C9: Relatlimab + Nivolumab SAV + Bevacizumab, D1: Nivolumab + Temozolomide, D2: Nivolumab + Rucaparib, D3: Nivolumab + Daratumumab, D4: Nivolumab + Bevacizumab, E1: Bevacizumab Monotherapy, E2: Regorafinib Monotherapy, E4: Leucovorin + Oxaliplatin + Fluorouracil, E5: Enzalutamide Monotherapy, E6: Sunitinib Monotherapy, E7: Rucaparib Monotherapy, E8: Capecitabine Monotherapy, E9: Cabozantinib Monotherapy, E10: Pemetrexed Monotherapy, E11: Pembrolizumab Monotherapy, E3: Leucovorin + Fluorouracil


You can join if…

Open to people ages 18 years and up

  • Signed Written Informed Consent.
  • Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study.
  • On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.
  • WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.

You CAN'T join if...

  • Participant is not eligible for study treatment per the Parent Study eligibility criteria.
  • Participants not receiving clinical benefit as assessed by the Investigator.
  • Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.
  • Other protocol-defined Inclusion/Exclusion Criteria apply


  • UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Melanoma Center accepting new patients
    San Francisco California 94143 United States
  • Local Institution withdrawn
    San Francisco California 94115 United States
  • Huntsman Cancer Institute accepting new patients
    Salt Lake City Utah 84112-5550 United States


accepting new patients
Start Date
Completion Date
Bristol-Myers Squibb
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting
Phase 2 Cancer, General Research Study
Study Type
Expecting 1500 study participants
Last Updated